SpringWorks Therapeutics Anticipates CHMP Opinion on Nirogacestat Marketing Authorization Application in Q2 2025
27/4 16:40
SpringWorks Therapeutics expects the EMA to rule on nirogacestat's marketing authorization for desmoid tumors in Q2 2025....
|
|
|
27/4 16:40
SpringWorks Therapeutics expects the EMA to rule on nirogacestat's marketing authorization for desmoid tumors in Q2 2025....